Soligenix, Inc. (SNGX) analyst actions
Rating and price-target actions on SNGX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SNGX overview →
3 measured SNGX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| IBN Initiates Coverage of Soligenix Inc. | Press release | — | +3.04% | |
| Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma | Press release | -1.81% | -7.85% | |
| Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease | Press release | +0.00% | +1.38% |
Keep exploring
More SNGX: earnings → · SEC filings → · SNGX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
| Mersana Therapeutics, Inc. (MRSN) | 251 | -0.20% | 46% |
| Co-Diagnostics, Inc. (CODX) | 250 | 0.00% | 46% |
| argenx SE - American Depositary Shares (ARGX) | 249 | -0.02% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.